Evaluating the safety of HIV prevention medication for infants during pregnancy and breastfeeding
Evaluating Infant PrEP Exposure During Pregnancy and Breastfeeding
This study is looking at how safe it is for pregnant and new moms in Kenya to take a medication called PrEP to prevent HIV, and how it might affect their babies' growth and development during the first five years of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10654810 on NIH RePORTER |
What this research studies
This research investigates the safety of pre-exposure prophylaxis (PrEP) for HIV-negative pregnant and postpartum women in high HIV prevalence areas, particularly in Kenya. It aims to assess the exposure of infants to PrEP both in utero and through breastfeeding, and to evaluate the potential impacts on their growth, bone development, and neurocognitive outcomes up to the age of five. By analyzing hair samples from mother-infant pairs, the study will provide valuable data on the long-term effects of PrEP on infants. The research leverages an existing study infrastructure to extend follow-up and gather comprehensive safety profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-negative pregnant or postpartum women living in high HIV prevalence regions, particularly in Kenya.
Not a fit: Patients who are HIV-positive or those not pregnant or postpartum may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide critical insights into the safety of PrEP for infants, potentially leading to improved guidelines for HIV prevention in pregnant women.
How similar studies have performed: While there have been studies on PrEP, this research is unique as it focuses on long-term safety evaluations in infants, making it a novel approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Pintye, Jillian — University of Washington
- Study coordinator: Pintye, Jillian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.